Stimvia, a pioneering medical technology company specializing in neuromodulation for chronic disease treatment, has successfully completed its pilot study focused on Parkinson’s Disease (PD) and is expecting promising results.
“We are pleased to share preliminary findings indicating promising results. Patients have reported improvements in both the number of Parkinson’s disease symptoms and their overall quality of life. Furthermore, we have observed a notable reduction in resting tremor. While the precise data are still under rigorous evaluation, we remain cautiously optimistic about the potential implications of these outcomes,” states Prof. David Skoloudik, MD, Ph.D.,FESO, FEAN, the study’s lead and Vice-Dean for Science and Research at the Medical Faculty of Ostrava University.
Twelve patients with Parkinson’s Disease who met inclusion criteria participated in the study. For six weeks, patients used the URIS device for thirty-minute stimulation sessions daily. Following this phase, patients went six weeks without stimulation, during which they continued to be monitored to assess whether any positive effects persisted after the treatment ended.
“Since the URIS technology demonstrated a positive impact in treating Parkinson’s Disease, Stimvia plans substantial investment in further clinical trials to validate the method’s efficacy and safety. We believe our technology can introduce new, additive treatment modalities for millions of patients who currently have no other options, potentially offering a positive disease-modifying impact on those with Parkinson’s disease,” says Lukas Doskocil, CEO of Stimvia.
The company envisions treating a significant number of people with PD using its unique technology in the near future. In the United States alone, an estimated 1 million individuals are affected by these conditions, contributing to over 10 million patients globally. Parkinson’s disease ranks as the second most prevalent neurodegenerative disorder after Alzheimer’s disease.
SHARE
